MedTrace Logo

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

NCT04495179 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-08-09

Study results available
· View outcomes & findings →

Summary

This is a Phase II, international, open-label, two-arm, non-randomised study of AZD4635 in participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Progressive Metastatic Castrate-Resistant Prostate Cancer

Interventions

DRUG

AZD4635

Subjects will receive AZD4635 orally daily

DRUG

Durvalumab

Subjects will receive intravenous durvalumab every 4 weeks for Arm A and every 3 weeks for Arm B.

DRUG

Cabazitaxel

Subjects will receive intravenous cabazitaxel every 3 weeks

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Christopher J Sweeney, MBBS · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
150 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-04
Primary Completion
2021-11-01
Completion
2022-08-08
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04495179 on ClinicalTrials.gov